27.46
Precedente Chiudi:
$26.98
Aprire:
$27.605
Volume 24 ore:
995.59K
Relative Volume:
0.98
Capitalizzazione di mercato:
$2.08B
Reddito:
$399.58M
Utile/perdita netta:
$-54.04M
Rapporto P/E:
-36.61
EPS:
-0.75
Flusso di cassa netto:
$40.13M
1 W Prestazione:
+3.19%
1M Prestazione:
-10.14%
6M Prestazione:
-37.77%
1 anno Prestazione:
+28.26%
Veracyte Inc Stock (VCYT) Company Profile
Nome
Veracyte Inc
Settore
Industria
Telefono
(650) 243-6300
Indirizzo
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta VCYT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
VCYT
Veracyte Inc
|
27.46 | 2.08B | 399.58M | -54.04M | 40.13M | -0.75 |
![]()
TMO
Thermo Fisher Scientific Inc
|
401.90 | 152.06B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
196.02 | 135.91B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
524.91 | 41.29B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
115.80 | 31.79B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
152.32 | 24.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-20 | Iniziato | Craig Hallum | Buy |
2024-12-05 | Downgrade | Goldman | Buy → Neutral |
2024-11-15 | Iniziato | Wolfe Research | Outperform |
2024-10-16 | Iniziato | UBS | Buy |
2024-10-10 | Iniziato | Guggenheim | Buy |
2024-02-23 | Reiterato | Needham | Buy |
2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
2022-01-07 | Iniziato | Stephens | Overweight |
2021-11-18 | Ripresa | Goldman | Buy |
2021-06-15 | Iniziato | Raymond James | Outperform |
2021-02-18 | Ripresa | Needham | Buy |
2021-01-28 | Iniziato | Truist | Buy |
2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
2020-09-09 | Iniziato | Morgan Stanley | Underweight |
2019-07-31 | Iniziato | Lake Street | Buy |
2019-07-02 | Iniziato | Needham | Buy |
2018-11-29 | Downgrade | Janney | Buy → Neutral |
2018-10-31 | Aggiornamento | Janney | Neutral → Buy |
2017-11-07 | Downgrade | Janney | Buy → Neutral |
2017-11-07 | Downgrade | Piper Jaffray | Overweight → Neutral |
2017-08-31 | Ripresa | BTIG Research | Buy |
2016-11-14 | Ripresa | Leerink Partners | Outperform |
2015-12-18 | Iniziato | Cantor Fitzgerald | Buy |
2015-06-11 | Reiterato | Leerink Partners | Outperform |
2013-11-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Veracyte Inc Borsa (VCYT) Ultime notizie
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems - Benzinga
Veracyte chief commercial officer sells shares for $76,409 By Investing.com - Investing.com Canada
Veracyte chief commercial officer sells shares for $76,409 - Investing.com Australia
Cathie Wood’s ARK buys Veracyte, sells AvidXchange and 3D Systems stock - Investing.com
Insider Selling: John Leite Sells Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Top Companies in the NASDAQ Veracyte and Others by Kalkine - Kalkine Media
Two Sigma Advisers LP Cuts Stock Position in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte at Jefferies Global Healthcare Conference: Strategic Growth and Innovation - Investing.com Nigeria
Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant - Investing.com Australia
Veracyte (VCYT) Shares Pulled Back Despite Beating Expectations - MSN
Veracyte at William Blair Growth Stock Conference: Strategic Insights Unveiled - Investing.com Canada
Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO - MSN
Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research - BioSpace
Veracyte (VCYT) Showcases Findings at ASCO Annual Meeting | VCYT Stock News - GuruFocus
Veracyte to present multiple abstracts at ASCO - TipRanks
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research | VCYT Stock News - GuruFocus
Veracyte Inc (VCYT) Shares Gap Down to $26.74 on May 28 - GuruFocus
Veracyte: Upgrading To Neutral (NASDAQ:VCYT) - Seeking Alpha
Captrust Financial Advisors Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Scotiabank maintains Veracyte stock with $44 target - Investing.com
Scotiabank maintains Veracyte stock with $44 target By Investing.com - Investing.com India
Deutsche Bank AG Has $3.22 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte to Participate in Upcoming Investor Conferences - 01net
Veracyte to Participate in Upcoming Investor Conferences | VCYT Stock News - GuruFocus
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally? - Zacks Investment Research
BNP Paribas Financial Markets Sells 55,684 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
William Blair Estimates Veracyte’s Q2 Earnings (NASDAQ:VCYT) - Defense World
Stifel Financial Corp Sells 2,211 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte projects strong Decipher and Afirma growth, targets 22.5% adjusted EBITDA margin for 2025 - MSN
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next - simplywall.st
Veracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Veracyte (VCYT) and Inotiv (NOTV) - The Globe and Mail
Veracyte First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc earnings beat by $0.29, revenue topped estimates - Investing.com Nigeria
Veracyte (VCYT) Target Price Lowered by UBS | VCYT Stock News - GuruFocus
What Makes Veracyte (VCYT) a New Buy Stock - Yahoo Finance
Veracyte shares target cut to $41 by Needham, keeps buy rating - Investing.com Nigeria
Veracyte, Inc. (NASDAQ:VCYT) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Price Target for Veracyte (VCYT) Amid Growth Potential | VCYT Stock News - GuruFocus
UBS Cuts Price Target on Veracyte to $42 From $49, Keeps Buy Rating - marketscreener.com
VERACYTE, INC. SEC 10-Q Report - TradingView
Breaking Down Veracyte: 7 Analysts Share Their Views - Benzinga
Veracyte Inc Azioni (VCYT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):